- Home
- ATLO vs SKYE Comparison
ATLO vs SKYE Comparison
Compare ATLO & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLO
- SKYE
- Stock Information
- Founded
- ATLO 1903
- SKYE 2012
- Country
- ATLO United States
- SKYE United States
- Employees
- ATLO N/A
- SKYE N/A
- Industry
- ATLO Major Banks
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- ATLO Finance
- SKYE Health Care
- Exchange
- ATLO Nasdaq
- SKYE Nasdaq
- Market Cap
- ATLO 174.1M
- SKYE 172.9M
- IPO Year
- ATLO N/A
- SKYE N/A
- Fundamental
- Price
- ATLO $18.77
- SKYE $5.31
- Analyst Decision
- ATLO
- SKYE Strong Buy
- Analyst Count
- ATLO 0
- SKYE 5
- Target Price
- ATLO N/A
- SKYE $18.40
- AVG Volume (30 Days)
- ATLO 13.8K
- SKYE 146.6K
- Earning Date
- ATLO 10-18-2024
- SKYE 11-09-2024
- Dividend Yield
- ATLO 5.38%
- SKYE N/A
- EPS Growth
- ATLO N/A
- SKYE N/A
- EPS
- ATLO 1.06
- SKYE N/A
- Revenue
- ATLO $51,275,000.00
- SKYE N/A
- Revenue This Year
- ATLO N/A
- SKYE N/A
- Revenue Next Year
- ATLO N/A
- SKYE N/A
- P/E Ratio
- ATLO $17.38
- SKYE N/A
- Revenue Growth
- ATLO N/A
- SKYE N/A
- 52 Week Low
- ATLO $15.01
- SKYE $1.44
- 52 Week High
- ATLO $22.50
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- ATLO 51.85
- SKYE 42.98
- Support Level
- ATLO $18.27
- SKYE $5.71
- Resistance Level
- ATLO $18.69
- SKYE $7.11
- Average True Range (ATR)
- ATLO 0.47
- SKYE 0.58
- MACD
- ATLO 0.11
- SKYE -0.05
- Stochastic Oscillator
- ATLO 84.21
- SKYE 0.55
About ATLO Ames National Corporation
Ames National Corporation is a United States-based bank holding company. Through its subsidiaries, it provides checking, savings and time deposits, cash management services, merchant credit card processing, safe deposit boxes, wire transfers, direct deposit of payroll and social security checks, and automated/video teller machine access. Its loan portfolio comprises commercial, residential & agricultural real estate loans; agricultural & business operating loans & lines of credit; equipment loans; vehicle loans; personal loans; and mortgage loans. Its operations are conducted in central, north central, and south-central Iowa.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.